GPC Biotech AG

Bernd R. Seizinger, M.D., Ph.D., has been Chief Executive Officer of GPC Biotech since 1998. He joined GPC Biotech from Genome Therapeutics Corporation (now Oscient Pharmaceuticals Corpora-tion) of Waltham, Massachusetts, where he was Executive Vice President and Chief Scientific Officer (1996–1998). From 1992 to 1996, Dr. Seizinger was at Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, New Jersey, where he held the posts of Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances. From 1984 to 1992, Dr. Seizinger was at Harvard Medical School and Massachusetts General Hospital, where he served both as Associate Professor of Neuroscience at Harvard Medical School and Associate Geneticist and Director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital. Dr. Seizinger was a faculty member at the Department of Molecular Biology at Princeton University. He was awarded his M.D. from the Ludwig Maximilians University and his Ph.D. from the Max Planck Institute of Psychiatry, both in Munich. He is the recipient of a number of scientific awards and has authored over 100 scientific publications. He is a member of the Supervisory Boards of BioXell SpA and Santhera Pharmaceuticals AG.

Torsten Hombeck, Ph.D., has served as the Company’s Chief Financial Officer since January 2008. He previously was GPC Biotech’s Vice President, Finance. Dr. Hombeck joined the Company in 1999. Prior to joining GPC Biotech, he held positions in corporate finance and controlling, including financial oversight responsibility for South America, at Beiersdorf AG, an international branded consumer products company. Dr. Hombeck holds a Ph. D. in Finance and a Masters degree in business administration from the European Business School in Oestrich-Winkel, Germany. Dr. Hombeck also serves as a board member of Flakeboard America Ltd., a North American producer of composite wood products.

Brent Hatzis-Schoch joined GPC Biotech in 2003. Prior to joining GPC Biotech, Mr. Hatzis-Schoch was Associate General Counsel for Global Research & Development at Pharmacia Corporation, where he earlier held various senior legal positions in the transactional and international areas. Previously, he had been European legal counsel to Baxter Healthcare, based in Brussels, Belgium. He also spent several years in private practice in the United States and Germany. Mr. Hatzis-Schoch received his law degree from George Washington University, Washington D.C.

Prior to joining GPC Biotech in 2002, he held the position of Vice President Business Development at Double Twist, Inc., Oakland, CA, where he was responsible for creating alliances with a variety of genomics and proteomics companies. Prior to joining Double Twist, Mr. Freund was a project manager at the Boston Consulting Group, San Francisco, CA, and London, UK, where he managed assignments in the healthcare and high technology practice areas. Mr. Freund received his BA in Economics and Management Studies from the University of Cambridge, UK, and his MBA from Stanford University, CA.

Gregory H. Hamm joined GPC Biotech in 1999 as Vice President, Bioinformatics and Information Technology, as well as Site Head of the Princeton facility. In 2001, Mr. Hamm was also appointed Vice President, Corporate Integration, which includes responsibility for Human Resources worldwide. In 2007, Mr. Hamm assumed his present role as Senior Vice President, Human Resources & Corporate Integration, with continued responsibility for Information Technology and the Princeton site. Mr. Hamm was previously Vice President, Bioinformatics, at Genome Therapeutics Corporation (now Oscient Pharmaceuticals Corporation). Before 1995, Mr. Hamm was Director of the Molecular Biology Computing Laboratory at Rutgers University (U.S.). Earlier he was the founder of the EMBL Data Library and Head of Computing at the European Molecular Biology Laboratory (EMBL) in Heidelberg (Germany).

Sebastian Meier-Ewert, Ph.D., co-founder of GPC Biotech AG, serves as the Company's Senior Vice President and Chief Scientific Officer. He is also Chief Operating Officer of the Waltham facility. Prior to co-founding GPC Biotech, Dr. Meier-Ewert established and led a team of scientists working on gene expression analysis and bioinformatics at the Max Planck Institute for Molecular Genetics in Berlin. He also co-founded a consulting firm specializing in biotechnology know-how and technologies. Dr. Meier-Ewert studied biochemistry at University College, London. He completed his postgraduate training at the Imperial Cancer Research Fund in London and received his Ph.D. from the University of London. He is the recipient of several awards and author of more than 30 publications. Dr. Meier-Ewert is a member of the Super-visory Board of Immatics Biotechnologies GmbH.

Mr. Higgins manages Highland Capital Partners' investments in healthcare. He has over 20 years experience in venture capital and currently serves as a Director of Conor Medsystems, GenPath Pharmaceuticals, Helicos BioSciences, SmartBargains and WordWave. He formerly served as a Director of several public companies, including Community Health Systems, Mariner Health Group, Inc., New England Critical Care, and Renal Treatment Centers, Inc. In addition, he is President of the New England Venture Capital Association. Before forming Highland in 1987, Mr. Higgins was a general Partner at Charles River Ventures. Immediately prior to entering the venture capital industry, he spent four years as the Executive Director of the John A. Hartford Foundation. He was also Chief Executive of the Clark Foundation and the Burden Foundation. A former Assistant to the U.S. Secretary of Commerce and an Assistant to the head of the international division of the U.S. Treasury, Mr. Higgins has a BA in History from Harvard College and an MBA from the Harvard Business School.

John is a strategic and commercial development advisor to the biotechnology industry. He currently serves as Chairman of Altus Pharmaceuticals Inc. (NASDAQ: ALTU), as Senior Business Advisor to GPC Biotech AG (NASDAQ: GPCB), and as a consultant to Nomura Phase4 Ventures. He also serves as a director of Targacept Inc., Zygogen LLC, and Metastatix Inc. John was previously Executive Vice President, Business Development at SEQUUS Pharmaceuticals, Inc., where he was responsible for negotiating the acquisition of SEQUUS by ALZA Corporation. Prior to joining SEQUUS, John headed business development for VIVUS, Inc. and Genome Therapeutics Corporation (now Oscient), where he was responsible for establishing numerous pharmaceutical alliances. He was also co-founder and original CEO of IMPATH Laboratories, Inc., a leading cancer pathology reference laboratory (now a part of Genzyme). John received his M.B.A. from Harvard Business School and his B.S. from Stanford University. He can be reached at john@georgiavc.com john@georgiavc.com .

Managing Partner, Bear Stearns Health Innoventures Management, L.L.C. Jurgen Drews joined Bear Stearns from IBMP, a $70 million biotech venture fund, where he was co-founder and Chairman of the Board. From 1986 to 1997, Dr. Drews was President of Global Research and Development and a member of the Executive Committee at Hoffmann-La Roche. From 1970 to 1978 he was Head of Microbiology at the Sandoz Research Institute in Vienna. Between 1979 and 1982 he was Managing Director of this institute. He and Dr. Ryser co-authored several watershed articles on productivity in the pharmaceutical industry described on the following page. Dr. Drews is the author of the 1999 book "In Quest of Tomorrow's Medicines." He serves on the board of several leading biotech companies and is past President of the Brussels-based Senior Advisory Group on Biotechnology (later named EuropaBio). Dr. Drews is a professor of Internal Medicine at the University of Heidelberg, Germany, and a professor of Molecular Genetics at The University of Medicine and Dentistry, New Brunswick, NJ. Between 1998 and 2000 he also consulted for Orbimed Advisors LLC, a New York company managing health care funds. Dr. Drews received his M.D. degree from the Free University of Berlin and did postdoctoral work at the University of Frankfurt and Yale University. BSHI portfolio: Dr. Drews currently is the chairman of the supervisory board of Tegenero Immuno Therapeutics AG.

Array

Michael Lytton is our Executive Vice President, Corporate and Business Development, and has served in that position since February 2009. From 2001 to 2009, he was a General Partner at Oxford Bioscience Partners, a venture capital firm. From 1993 to 2000, he was Partner, Chairman of the Technology Group and a member of the Executive Committee of the law firm Edwards, Angell, Palmer & Dodge LLP. From 1984 to 1993, Mr. Lytton was a Junior Partner and Co-Chairman of the Biotechnology Practice of the law firm Wilmer Hale.